/IVVD
IVVD Stock - Invivyd, Inc.
Healthcare|BiotechnologyNASDAQ
$2.30+0.44%
+$0.01 (+0.44%) • Dec 19
89
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
High Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.100
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.95
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+313.0%upside
Target: $9.50
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for IVVD
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$2.28 – $2.32
TARGET (TP)$9.50
STOP LOSS$2.12
RISK/REWARD1:40.0
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.62
52W High$3.07
52W Low$0.35
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $25.38M | N/A | N/A | N/A | N/A |
| Gross Profit | $23.77M | N/A | N/A | N/A | N/A |
| Gross Margin | 93.6% | N/A | N/A | N/A | N/A |
| Operating Income | $-176,876,000 | $-212,758,000 | $-248,031,000 | $-226,908,000 | $-111,989,162 |
| Net Income | $-169,925,000 | $-198,643,000 | $-241,317,000 | $-226,790,000 | $-111,975,447 |
| Net Margin | -669.4% | N/A | N/A | N/A | N/A |
| EPS | $-1.43 | $-1.81 | $-2.17 | $-2.11 | $-0.59 |
Company Overview
Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatment and prevention of coronavirus disease. Adagio Therapeutics, Inc. has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was incorporated in 2020 and is based in Waltham, Massachusetts.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
2
50%
Hold / Neutral
2
50%
Sell / Underperform
0%
Analyst Consensus🟡 Mixed
2 Bullish2 Neutral/Bearish
Price Targets
$8
Average Target
↑ 230.4% Upside
Now
$4
Low
$8
Average
$10
High
Based on 5 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| November 25th 2025 | D. Boral Capital | Downgrade | Hold | - |
| October 6th 2025 | Cantor Fitzgerald | Initiation | Overweight | $10 |
| April 5th 2024 | Guggenheim | Upgrade | Buy | $9 |
| March 26th 2024 | Morgan Stanley | Upgrade | Overweight | $10← $4 |
| December 19th 2023 | Morgan Stanley | Upgrade | Equal Weight | $4← $1 |
| May 1st 2023 | H.C. Wainwright | Initiation | Buy | $5 |
Earnings History & Surprises
IVVDBeat Rate
44%
Last 18 quarters
Avg Surprise
-23.5%
EPS vs Estimate
Beats / Misses
8/10
Last 12 quarters
Latest EPS
$-0.06
Q4 2025
EPS Surprise History
Q1 24
-63.4%
$-0.67vs$-0.41
Q2 24
+25.5%
$-0.38vs$-0.51
Q3 24
-8.1%
$-0.40vs$-0.37
Q4 24
-54.5%
$-0.51vs$-0.33
Q1 25
+40.0%
$-0.15vs$-0.25
Q2 25
-250.0%
$-0.14vs$-0.04
Q3 25
-200.0%
$-0.12vs$-0.04
Q4 25
-20.0%
$-0.06vs$-0.05
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 13, 2026 | — | — | — | — |
Q1 2026 | Mar 19, 2026 | $-0.06 | — | — | — |
Q4 2025 | Nov 6, 2025 | $-0.05 | $-0.06 | -20.0% | ✗ MISS |
Q3 2025 | Aug 14, 2025 | $-0.04 | $-0.12 | -200.0% | ✗ MISS |
Q2 2025 | May 15, 2025 | $-0.04 | $-0.14 | -250.0% | ✗ MISS |
Q1 2025 | Mar 20, 2025 | $-0.25 | $-0.15 | +40.0% | ✓ BEAT |
Q4 2024 | Nov 14, 2024 | $-0.33 | $-0.51 | -54.5% | ✗ MISS |
Q3 2024 | Aug 14, 2024 | $-0.37 | $-0.40 | -8.1% | ✗ MISS |
Q2 2024 | May 9, 2024 | $-0.51 | $-0.38 | +25.5% | ✓ BEAT |
Q1 2024 | Mar 28, 2024 | $-0.41 | $-0.67 | -63.4% | ✗ MISS |
Q4 2023 | Nov 9, 2023 | $-0.54 | $-0.36 | +33.3% | ✓ BEAT |
Q3 2023 | Aug 10, 2023 | $-0.40 | $-0.46 | -15.0% | ✗ MISS |
Q2 2023 | May 11, 2023 | $-0.36 | $-0.32 | +11.1% | ✓ BEAT |
Q1 2023 | Mar 23, 2023 | $-0.39 | $-0.41 | -5.1% | ✗ MISS |
Q4 2022 | Nov 10, 2022 | $-0.46 | $-0.42 | +8.7% | ✓ BEAT |
Q3 2022 | Aug 15, 2022 | $-0.57 | $-0.47 | +17.5% | ✓ BEAT |
Q2 2022 | May 13, 2022 | $-0.82 | $-0.93 | -13.4% | ✗ MISS |
Q1 2022 | Mar 30, 2022 | $-1.03 | $-0.77 | +25.2% | ✓ BEAT |
Q4 2021 | Nov 15, 2021 | $-0.74 | $-0.98 | -32.4% | ✗ MISS |
Q3 2021 | Sep 20, 2021 | $-0.80 | $-0.18 | +77.5% | ✓ BEAT |
Latest News
D. Boral Capital Downgrades Invivyd to Hold
📉 NegativeBenzinga•Nov 25, 2025, 01:03 PM
Invivyd Announced It Has Identified And Nominated For Preclinical Development A Potentially Best-in-class Monoclonal Antibody Candidate For The Prevention Of Respiratory Syncytial Virus Among Neonates, Infants, And Children
📈 PositiveBenzinga•Nov 24, 2025, 12:17 PM
Invivyd shares are trading lower after the company announced the pricing of its $125 million underwritten public offering.
📉 NegativeBenzinga•Nov 18, 2025, 01:59 PM
Reported Earlier, Invivyd Prices $125M Underwritten Public Offering Including 44M Common Shares At $2.50 Per Share And 6M Pre Funded Warrants At $2.4999
➖ NeutralBenzinga•Nov 18, 2025, 07:10 AM
Invivyd prices $125M stock offering at $2.50 per share
➖ NeutralSeeking Alpha•Nov 18, 2025, 06:39 AM
IVVD stock has given up its prior loss. Invivyd shares were trading lower after the company announced a proposed public offering.
➖ NeutralBenzinga•Nov 17, 2025, 09:38 PM
Invivyd shares are trading lower after the company announced a proposed public offering.
📉 NegativeBenzinga•Nov 17, 2025, 09:07 PM
Invivyd Announces Proposed Public Offering of Common Stock, Size Not Given
➖ NeutralBenzinga•Nov 17, 2025, 09:02 PM
IVVD stock has given up its prior gain. Invivyd shares were trading higher after the company reported better-than-expected Q3 financial results.
➖ NeutralBenzinga•Nov 6, 2025, 03:57 PM
Invivyd shares are trading higher after the company reported better-than-expected Q3 financial results.
📈 PositiveBenzinga•Nov 6, 2025, 02:28 PM
Invivyd Q3 EPS $(0.06) Beats $(0.08) Estimate, Sales $13.129M Beat $13.100M Estimate
📈 PositiveBenzinga•Nov 6, 2025, 12:06 PM
HC Wainwright & Co. Maintains Buy on Invivyd, Raises Price Target to $10
📈 PositiveBenzinga•Nov 3, 2025, 12:15 PM
HC Wainwright & Co. Maintains Buy on Invivyd, Raises Price Target to $10
📈 PositiveBenzinga•Oct 31, 2025, 03:37 PM
D. Boral Capital Maintains Buy on Invivyd, Raises Price Target to $2
📈 PositiveBenzinga•Oct 6, 2025, 06:03 PM
Invivyd shares are trading higher after the company's VYD2311 received FDA clearance for trials.
📈 PositiveBenzinga•Oct 6, 2025, 03:24 PM
The FDA Clears Invivyd's Investigational New Drug Application And Provided Feedback To Advance Its REVOLUTION Clinical Development Program For VYD2311, A Vaccine Alternative Monoclonal Antibody Candidate To Prevent COVID Infection
📈 PositiveBenzinga•Oct 6, 2025, 11:12 AM
Cantor Fitzgerald Initiates Coverage On Invivyd with Overweight Rating, Announces Price Target of $10
📈 PositiveBenzinga•Oct 6, 2025, 11:09 AM
Invivyd Filed For $350M Mixed Shelf Offering
➖ NeutralBenzinga•Oct 2, 2025, 08:15 PM
Invivyd shares are trading higher after Point72 hedge-fund manager, Steve Cohen, disclosed a 8% passive stake in the company.
📈 PositiveBenzinga•Aug 28, 2025, 04:13 PM
Point72 Hedge-Fund Manager, Steve Cohen, Discloses 8% Passive Stake In Invivyd
📈 PositiveBenzinga•Aug 27, 2025, 08:58 PM
Frequently Asked Questions about IVVD
What is IVVD's current stock price?
Invivyd, Inc. (IVVD) is currently trading at $2.30 per share. The stock has moved +0.44% today.
What is the analyst price target for IVVD?
The average analyst price target for IVVD is $9.50, based on 1 analyst.
What sector is Invivyd, Inc. in?
Invivyd, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is IVVD's market cap?
Invivyd, Inc. has a market capitalization of $0.31 billion, making it a small-cap company.
Does IVVD pay dividends?
No, Invivyd, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorCCCC
C4 Therapeutics, Inc.
$2.03
Mkt Cap: $0.1B
CDXS
Codexis, Inc.
$1.66
Mkt Cap: $0.1B
GNFT
Genfit S.A.
$5.61
Mkt Cap: $0.3B
IMDX
Insight Molecular Diagnostics Inc.
$5.41
Mkt Cap: $0.2B
NTHI
Neonc Technologies Holdings, Inc.
$7.01
Mkt Cap: $0.1B
OABI
OmniAb, Inc.
$2.09
Mkt Cap: $0.2B
OBIO
Orchestra BioMed Holdings, Inc.
$4.35
Mkt Cap: $0.2B
SGMO
Sangamo Therapeutics, Inc.
$0.45
Mkt Cap: $0.2B
SLS
SELLAS Life Sciences Group, Inc.
$2.36
Mkt Cap: $0.2B
TARA
Protara Therapeutics, Inc.
$5.27
Mkt Cap: $0.2B
Explore stocks similar to IVVD for comparison